Biotech News
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
ir.nucana.com2026-05-06 15:15 EST
NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response Preclinical Data Corroborate Immunogenic Effects of NUC-3373